S&P 500 Futures
(-0.08%) 5 304.25 points
Dow J Futures
(-0.09%) 40 140 points
Nasdaq Futures
(-0.05%) 18 465 points
Oil
(-0.07%) $83.11
Gas
(-0.62%) $1.752
Gold
(0.73%) $2 254.80
Silver
(0.74%) $25.10
Platinum
(0.21%) $923.00
USD/EUR
(0.13%) $0.928
USD/NOK
(0.13%) $10.86
USD/GBP
(0.04%) $0.793
USD/RUB
(-0.04%) $92.54

Realtime updates for Akeso Inc [9926.HK]

Exchange: HKSE Sector: Biotechnology Industry: Biotechnology
Last Updated28 Mar 2024 @ 04:08

0.00% HKD 46.65

Live Chart Being Loaded With Signals

Commentary (28 Mar 2024 @ 04:08):

Warning: Trying to access array offset on null in /home/getagraph/public_html/stock.php on line 302

Akeso, Inc., a biopharmaceutical company, researches, develops, manufactures, and commercializes therapies. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer (GC), gastroesophageal junction (GEJ) adenocarcinoma, hepatocellular carcinoma (HCC), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), nasopharyngeal carcinoma (NPC), clear cell renal cell carcinoma, and solid tumors; and AK112, a PD-1/VEGF bi-specific antibody to treat solid and gynecological tumors, NSCLC, SCLC, and triple-negative breast cancer (TNBC)...

Stats
Today's Volume 3.23M
Average Volume 4.65M
Market Cap 39.15B
EPS HKD0 ( 2024-03-18 )
Last Dividend HKD0 ( N/A )
Next Dividend HKD0 ( N/A )
P/E 17.74
ATR14 HKD0.0450 (0.10%)

Volume Correlation

Long: 0.30 (neutral)
Short: 0.89 (strong)
Signal:(45.297) Same movement expected

Akeso Inc Correlation

10 Most Positive Correlations
10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Akeso Inc Correlation - Currency/Commodity

The country flag -0.35
( neutral )
The country flag -0.12
( neutral )
The country flag 0.00
( neutral )
The country flag 0.06
( neutral )
The country flag 0.26
( neutral )
The country flag -0.40
( neutral )

Akeso Inc Financials

Annual 2022
Revenue: HKD837.66M
Gross Profit: HKD734.54M (87.69 %)
EPS: HKD-1.420
Q2 2023
Revenue: HKD3.68B
Gross Profit: HKD3.60B (97.86 %)
EPS: HKD3.01
Q4 2022
Revenue: HKD674.52M
Gross Profit: HKD599.89M (88.94 %)
EPS: HKD-0.640
Q2 2022
Revenue: HKD163.14M
Gross Profit: HKD134.65M (82.54 %)
EPS: HKD-0.770

Financial Reports:

No articles found.

Akeso Inc

Akeso, Inc., a biopharmaceutical company, researches, develops, manufactures, and commercializes therapies. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer (GC), gastroesophageal junction (GEJ) adenocarcinoma, hepatocellular carcinoma (HCC), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), nasopharyngeal carcinoma (NPC), clear cell renal cell carcinoma, and solid tumors; and AK112, a PD-1/VEGF bi-specific antibody to treat solid and gynecological tumors, NSCLC, SCLC, and triple-negative breast cancer (TNBC). It is also developing AK105, a PD-1 monoclonal antibody to treat NSCLC, NPC, classic Hodgkin's lymphoma (R/R cHL), HCC, head and neck cancer, thyroid cancer, mesothelioma and thymic cancer, ESCC, UC, GC, GEJ, cholangiocarcinoma, neuroendocrine tumor, and mismatch repair deficient solid tumor; AK117, a CD47 monoclonal antibody to treat myelodysplastic syndrome, acute myeloid leukemia, GC, GEJ, ESCC, TNBC, HNSCC, R/R cHL, NPC, NSCLC, and solid tumors/lymphoma; AK119, a CD73 monoclonal antibody for treating solid tumors; and AK109, a VEGFR-2 monoclonal antibody to treat solid tumors and gastric cancer. In addition, the company develops AK120, an IL-4R monoclonal antibody to treat moderate-to-severe atopic dermatitis and asthma, and eosinophilic esophagitis; AK101, an IL-12/IL-23 monoclonal antibody to treat moderate-to-severe psoriasis and ulcerative colitis; AK111, an IL-17 monoclonal antibody to treat moderate-to-severe psoriasis and ankylosing spondylitis; and AK102, a PCSK9 monoclonal antibody to treat hypercholesterolemia. Further, its preclinical product includes AK127, a TIGIT monoclonal antibody to treat solid tumors; and AK115, a NGF monoclonal antibody. The company has collaboration agreements with Pfizer Pharmaceuticals, AstraZeneca Pharmaceuticals, and MD Anderson Medical Institute. Akeso, Inc. was founded in 2012 and is headquartered in Zhongshan, the People's Republic of China.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators